Chinese regulators have granted Boston Scientific approval to market its Alair Bronchial Thermoplasty device in that country. The device, which the company acquired through its $193.5 million purchase of Asthmatx in 2010, is designed to treat severe asthma patients who have failed to respond to long-acting beta-agonists or inhaled corticosteroids.

Related Summaries